Actelion Ltd (ALIOF) 133.3300 $ALIOF
ZS Pharma Corporate Statement
GlobeNewswire - Thu Sep 10, 4:31PM CDT
ZS Pharma, Inc. (Nasdaq:ZSPH), today confirmed that it has participated in preliminary discussions with Actelion Ltd. (OTC:ALIOF) regarding a potential strategic transaction. ZS Pharma regularly and routinely explores opportunities with various strategic partners and will continue to do so. These discussions may or may not lead to any transaction. ZS Pharma does not intend to comment further on market speculation or disclose any developments unless and until it otherwise deems further disclosure is appropriate or required.
ZSPH: 76.99 (+2.26)
ACTELION STATEMENT
Thomson Reuters ONE - Thu Sep 10, 4:15PM CDT
Actelion Pharmaceuticals Ltd / ACTELION STATEMENT . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
ZSPH: 76.99 (+2.26)
Actelion's Chief Scientific Officer Martine Clozel awarded the Tomoh Masaki award by the 14th International Conferences on Endothelin
Thomson Reuters ONE - Sat Sep 05, 1:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion's Chief Scientific Officer Martine Clozel awarded the Tomoh Masaki award by the 14th International Conferences on Endothelin . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Intercept's (ICPT) OCA Under Priority Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Tue Sep 01, 4:54PM CDT
Intercept Pharmaceuticals' (ICPT) NDA for obeticholic acid has been accepted by the FDA for priority review for the treatment of primary biliary cirrhosis.
GILD: 109.63 (+2.38), ICPT: 197.48 (+4.66), REGN: 533.30 (+2.08)
Global Pulmonary Arterial Hypertension (PAH) Market: Trends & Opportunities 2015-2019
M2 - Tue Sep 01, 4:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/43kmtp/global_pulmonary) has announced the addition of the "Global Pulmonary Arterial Hypertension (PAH) Market: Trends & Opportunities (2015-2019)" report to their offering. The report titled Global PAH Market: Trends and Opportunities (2015-2019), analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension (PAH) market. The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019, considering 2014 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2015 to 2019. Over the next five years, Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs. The report provides detailed analysis of the global PAH market sizing and growth by type for the period 2010-2014. The market is further segment by drug mechanism and different dosage forms. The analysis of PAH individual drugs sales are also provided in the report. The report profiles key market players such as Actelion Ltd., United Therapeutics Ltd. and SteadyMed Ltd. on the basis of attributes such as company overview, recent developments, strategies adopted by the market leaders to ensure growth, sustainability, financial overview and recent developments. Company Coverage - Actelion Limited - United Therapeutics Limited - SteadyMed Limited PAH Drug Mechanism - Endothelin Receptor Antagonists (ERA) - PDE 5 Inhibitors - Prostacyclins - sGC Stimulator Key Topics Covered: 1. Executive Summary 2. Pulmonary Arterial Hypertension (PAH): An Introduction 3. Global Pulmonary Arterial Hypertension (PAH) Market: An Analysis 4. Global PAH Market Share: An Analysis 5. Patch Pump Technology Market: An Analysis 6. Market Dynamics:Global PAH Market 7. Competitive Landscape:Global PAH Market 8. Company Profiles:Global PAH Market For more information visit http://www.researchandmarkets.com/research/43..._pulmonary
UTHR: 155.11 (+2.35), STDY: 3.55 (unch)
Seres (MCRB) Up on Orphan Drug Status for Lead Candidate
Zacks Equity Research - Zacks Investment Research - Mon Aug 24, 1:50PM CDT
Seres Therapeutics (MCRB) announced that SER-109 received orphan drug status from the FDA for the prevention of recurrent Clostridium difficile infection.
GILD: 109.63 (+2.38), MCRB: 48.66 (+0.95), REGN: 533.30 (+2.08)
Seattle Genetics' Adcetris Label Expanded in the U.S.
Zacks Equity Research - Zacks Investment Research - Tue Aug 18, 3:35PM CDT
Seattle Genetics' (SGEN) Adcetris receives FDA nod for Hodgkin lymphoma in patients running a high risk of relapse or progression in post-transplant setting.
SGEN: 45.01 (+3.43), AMAG: 53.00 (-4.65)
Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of nearly 60%
M2 - Tue Aug 18, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6ddnn/analyzing_the) has announced the addition of the "Analyzing the Global Biotechnology Industry 2015" report to their offering. Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues. Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment. The research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies. Key Topics Covered: A. Executive Summary B. Industry Definition C. Global Biotechnology Industry D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis E. Blurring Differences between Biotech & Pharma Companies F. Global Biotechnology Industry: Market Trends & Challenges G. Global Biotechnology Industry: Analysis of Key Markets H. Global Biotechnology Industry: Major Players Companies Mentioned - AbbVie Inc. - Abbott Laboratories - Acorda Therapeutics Inc. - Actelion Ltd - Amgen, Inc. - Amylin Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Baxter International Inc. - Biocon Limited - Biogen Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CSL Limited - Celgene Corporation - Covance Inc. - Crucell N.V. - Cubist Pharmaceuticals - Daiichi Sankyo Co., Ltd. - Esteve Group - F. Hoffmann-La Roche AG - GE Healthcare - Gentium S.p.A. - Genzyme Corporation - Gilead Sciences, Inc. - Grifols SA - ImmunoGen, Inc. - Johnson & Johnson - Menarini Group - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - MorphoSys AG - Novartis AG For more information visit http://www.researchandmarkets.com/research/r6...lyzing_the
ACOR: 33.07 (+0.14), CVD: 106.42 (-0.71), JNJ: 92.93 (+0.21), ABBV: 59.35 (-0.23), ABT: 43.41 (+0.29), CBSTZ: 0.06 (unch), IMGN: 13.86 (+0.59), AMGN: 153.21 (+0.07), BMY: 59.22 (+0.47), GRFS: 32.15 (+0.40), GILD: 109.63 (+2.38), BAX: 36.02 (-0.05), AZN: 33.30 (+0.02), MRK: 52.09 (-0.63), NVS: 96.55 (+0.28), CELGZ: 1.93 (+0.07)
Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015 - Summarizes all the dormant and discontinued pipeline projects
M2 - Mon Aug 17, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q7drg7/glioblastoma) has announced the addition of the "Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. Summary This, Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects - A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - AB Science - AbbVie Inc. - Actelion Ltd - Actinium Pharmaceuticals, Inc. - Actinogen Limited - Activartis Biotech GmbH - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advanced Cancer Therapeutics - Advenchen Laboratories, LLC - Agenus, Inc. - AGY Therapeutics, Inc. - Amal Therapeutics SA - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AngioChem Inc. - Apogenix GmbH - Argon Pharma S.L. - Ariad Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Axelar AB - Bexion Pharmaceuticals, LLC. - biOasis Technologies Inc. - BioCancell Ltd - Biomar Microbial Technologies - Bioncotech Therapeutics S.L. - Biovista Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/q7...ioblastoma
ATNM: 2.44 (+0.07), ADRO: 20.40 (+0.27), AMBX: (), AZN: 33.30 (+0.02), AMGN: 153.21 (+0.07), AMPE: 3.12 (+0.14), ABBV: 59.35 (-0.23), BMY: 59.22 (+0.47), AAAP: ()
Hypertension - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hypertension
M2 - Fri Aug 14, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gn56xn/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Hypertension - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: - Introduction - Hypertension Overview - Therapeutics Development - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - Hypertension - Therapeutics Assessment - Drug Profiles - Hypertension - Recent Pipeline Updates - Hypertension - Dormant Projects - Hypertension - Discontinued Products - Hypertension - Product Development Milestones Companies Mentioned - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Ahn-Gook Pharmaceutical Co., Ltd. - Alnylam Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Angion Biomedica Corp. - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Bio-inRen - Biocon Limited - Biolab Sanus Farmaceutica Ltda. - BioLineRx, Ltd. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Cellceutix Corporation - Celsion Corporation - Chong Kun Dang Pharmaceutical Corp. - CJ CheilJedang Corp. - Conatus Pharmaceuticals Inc. - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dong-A Socio Group - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/gn...pertension
CYTK: 7.31 (-0.08), CNAT: 4.44 (+0.10), CLDN: 1.22 (+0.02), LLY: 81.80 (+0.96), CLSN: 2.04 (-0.09), ASND: 20.60 (+0.05), ABBV: 59.35 (-0.23), ANAC: 141.14 (+1.10), ARNA: 2.86 (+0.15)
Systemic Lupus Erythematosus: Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Thu Aug 13, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2p7pm/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Systemic Lupus Erythematosus and enlists all their major and minor projects Companies Mentioned - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Kineta, Inc. - Kymab Limited - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - National Pharmaceutical Corp. - Neovacs SA - Nippon Chemiphar Co., Ltd. - Padlock Therapeutics, Inc. - Pfizer Inc. - Plexxikon Inc. - RedHill Biopharma Ltd. - Redx Pharma Ltd - Resolve Therapeutics, LLC - Sanofi - Sarepta Therapeutics, Inc. - SATT Conectus Alsace SAS - SBI Biotech Co., Ltd. - Seattle Genetics, Inc. - Takeda Pharmaceutical Company Limited - Therapix Biosciences Ltd - UCB S.A. - Xencor, Inc. - XTL Biopharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/c2...emic_lupus
RDHL: 14.47 (+0.62), JNJ: 92.93 (+0.21), ANTH: 8.03 (-0.15), SRPT: 35.94 (+1.49), ABBV: 59.35 (-0.23), XNCR: 16.39 (-0.49), CBMG: 22.85 (-0.01), MGNX: 26.64 (+0.29), IMMU: 2.22 (+0.01), PFE: 32.97 (+0.35), AMGN: 153.21 (+0.07), BMY: 59.22 (+0.47), GSK: 40.26 (+0.02), ARGS: 6.22 (-0.02), SGEN: 45.01 (+3.43), CELGZ: 1.93 (+0.07)
Mallinckrodt to Acquire Therakos, Boost Hospital Business
Zacks Equity Research - Zacks Investment Research - Tue Aug 11, 2:55PM CDT
Mallinckrodt (MNK) entered into a definitive agreement to acquire Therakos, Inc. from The Gores Group in a transaction valued at roughly $1.325 billion.
MNK: 82.08 (-0.92), VRX: 225.64 (-3.15), CORT: 5.06 (+0.01)
Catalyst Pharmaceuticals' Loss Wider Y/Y, Firdapse in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 11, 10:44AM CDT
Catalyst Pharmaceuticals (CPRX) reported second-quarter 2015 loss of 6 cents per share, wider than the Zacks Consensus Estimate of a loss of 7 cents.
VRX: 225.64 (-3.15), CPRX: 3.90 (-0.24), CORT: 5.06 (+0.01)
Merrimack Pharmaceuticals' Q2 Loss Wider, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 11, 9:50AM CDT
Merrimack Pharmaceuticals (MACK) reported second-quarter 2015 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 28 cents.
MACK: 10.48 (+0.04), BXLT: 35.81 (+0.80), CORT: 5.06 (+0.01)
Dyax (DYAX) Shows Strength: Stock Adds 6.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 7:51AM CDT
Dyax Corp. (DYAX) was a big mover last session, as its shares rose almost 7% on the day.
DYAX: 22.84 (+0.52)
Sarepta Posts Narrower-than-Expected Loss in Q2, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 4:58PM CDT
Sarepta Therapeutics (SRPT) reported a loss of $1.01 per share in the second quarter of 2015, much narrower than the Zacks Consensus Estimate of a loss of $1.21.
BMRN: 132.88 (-0.20), GILD: 109.63 (+2.38), SRPT: 35.94 (+1.49)
Emergent BioSolutions Tops on Q2 Earnings, Plans Spin-Off - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 4:55PM CDT
Emergent (EBS) reported earnings of 36 cents per share in the second quarter of 2015.
BIIB: 315.37 (+2.75), EBS: 32.58 (+0.39), AMAG: 53.00 (-4.65)
Jazz Pharmaceuticals Misses on Q2 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 2:12PM CDT
Jazz Pharmaceuticals (JAZZ) reported second-quarter 2015 earnings of $2.11 per share, substantially lower than the Zacks Consensus Estimate of $2.16.
GILD: 109.63 (+2.38), JAZZ: 160.62 (-0.21), LGND: 94.95 (+1.59)
Ironwood's Q2 Loss Wider than Expected, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 12:55PM CDT
Ironwood Pharmaceuticals (IRWD) reported a second-quarter 2015 loss of 34 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents.
AGN: 295.24 (+1.64), IRWD: 11.62 (+0.50), EXAS: 19.64 (-0.36)
Osiris Therapeutics' Q2 Earnings & Revenues Grow Y/Y - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 06, 12:50PM CDT
Osiris Therapeutics' (OSIR) revenues are growing significantly - the sales force effort, improving Medicare and private reimbursement coverage should continue driving revenues.
GILD: 109.63 (+2.38), OSIR: 19.32 (+0.52), AMAG: 53.00 (-4.65)
ZS Pharma Corporate Statement
GlobeNewswire - Thu Sep 10, 4:31PM CDT
ZS Pharma, Inc. (Nasdaq:ZSPH), today confirmed that it has participated in preliminary discussions with Actelion Ltd. (OTC:ALIOF) regarding a potential strategic transaction. ZS Pharma regularly and routinely explores opportunities with various strategic partners and will continue to do so. These discussions may or may not lead to any transaction. ZS Pharma does not intend to comment further on market speculation or disclose any developments unless and until it otherwise deems further disclosure is appropriate or required.
ZSPH: 76.99 (+2.26)
ACTELION STATEMENT
Thomson Reuters ONE - Thu Sep 10, 4:15PM CDT
Actelion Pharmaceuticals Ltd / ACTELION STATEMENT . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
ZSPH: 76.99 (+2.26)
Actelion's Chief Scientific Officer Martine Clozel awarded the Tomoh Masaki award by the 14th International Conferences on Endothelin
Thomson Reuters ONE - Sat Sep 05, 1:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion's Chief Scientific Officer Martine Clozel awarded the Tomoh Masaki award by the 14th International Conferences on Endothelin . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Intercept's (ICPT) OCA Under Priority Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Tue Sep 01, 4:54PM CDT
Intercept Pharmaceuticals' (ICPT) NDA for obeticholic acid has been accepted by the FDA for priority review for the treatment of primary biliary cirrhosis.
GILD: 109.63 (+2.38), ICPT: 197.48 (+4.66), REGN: 533.30 (+2.08)
Global Pulmonary Arterial Hypertension (PAH) Market: Trends & Opportunities 2015-2019
M2 - Tue Sep 01, 4:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/43kmtp/global_pulmonary) has announced the addition of the "Global Pulmonary Arterial Hypertension (PAH) Market: Trends & Opportunities (2015-2019)" report to their offering. The report titled Global PAH Market: Trends and Opportunities (2015-2019), analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension (PAH) market. The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019, considering 2014 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2015 to 2019. Over the next five years, Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs. The report provides detailed analysis of the global PAH market sizing and growth by type for the period 2010-2014. The market is further segment by drug mechanism and different dosage forms. The analysis of PAH individual drugs sales are also provided in the report. The report profiles key market players such as Actelion Ltd., United Therapeutics Ltd. and SteadyMed Ltd. on the basis of attributes such as company overview, recent developments, strategies adopted by the market leaders to ensure growth, sustainability, financial overview and recent developments. Company Coverage - Actelion Limited - United Therapeutics Limited - SteadyMed Limited PAH Drug Mechanism - Endothelin Receptor Antagonists (ERA) - PDE 5 Inhibitors - Prostacyclins - sGC Stimulator Key Topics Covered: 1. Executive Summary 2. Pulmonary Arterial Hypertension (PAH): An Introduction 3. Global Pulmonary Arterial Hypertension (PAH) Market: An Analysis 4. Global PAH Market Share: An Analysis 5. Patch Pump Technology Market: An Analysis 6. Market Dynamics:Global PAH Market 7. Competitive Landscape:Global PAH Market 8. Company Profiles:Global PAH Market For more information visit http://www.researchandmarkets.com/research/43..._pulmonary
UTHR: 155.11 (+2.35), STDY: 3.55 (unch)
Seres (MCRB) Up on Orphan Drug Status for Lead Candidate
Zacks Equity Research - Zacks Investment Research - Mon Aug 24, 1:50PM CDT
Seres Therapeutics (MCRB) announced that SER-109 received orphan drug status from the FDA for the prevention of recurrent Clostridium difficile infection.
GILD: 109.63 (+2.38), MCRB: 48.66 (+0.95), REGN: 533.30 (+2.08)
Seattle Genetics' Adcetris Label Expanded in the U.S.
Zacks Equity Research - Zacks Investment Research - Tue Aug 18, 3:35PM CDT
Seattle Genetics' (SGEN) Adcetris receives FDA nod for Hodgkin lymphoma in patients running a high risk of relapse or progression in post-transplant setting.
SGEN: 45.01 (+3.43), AMAG: 53.00 (-4.65)
Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of nearly 60%
M2 - Tue Aug 18, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6ddnn/analyzing_the) has announced the addition of the "Analyzing the Global Biotechnology Industry 2015" report to their offering. Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues. Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment. The research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies. Key Topics Covered: A. Executive Summary B. Industry Definition C. Global Biotechnology Industry D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis E. Blurring Differences between Biotech & Pharma Companies F. Global Biotechnology Industry: Market Trends & Challenges G. Global Biotechnology Industry: Analysis of Key Markets H. Global Biotechnology Industry: Major Players Companies Mentioned - AbbVie Inc. - Abbott Laboratories - Acorda Therapeutics Inc. - Actelion Ltd - Amgen, Inc. - Amylin Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Baxter International Inc. - Biocon Limited - Biogen Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CSL Limited - Celgene Corporation - Covance Inc. - Crucell N.V. - Cubist Pharmaceuticals - Daiichi Sankyo Co., Ltd. - Esteve Group - F. Hoffmann-La Roche AG - GE Healthcare - Gentium S.p.A. - Genzyme Corporation - Gilead Sciences, Inc. - Grifols SA - ImmunoGen, Inc. - Johnson & Johnson - Menarini Group - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - MorphoSys AG - Novartis AG For more information visit http://www.researchandmarkets.com/research/r6...lyzing_the
ACOR: 33.07 (+0.14), CVD: 106.42 (-0.71), JNJ: 92.93 (+0.21), ABBV: 59.35 (-0.23), ABT: 43.41 (+0.29), CBSTZ: 0.06 (unch), IMGN: 13.86 (+0.59), AMGN: 153.21 (+0.07), BMY: 59.22 (+0.47), GRFS: 32.15 (+0.40), GILD: 109.63 (+2.38), BAX: 36.02 (-0.05), AZN: 33.30 (+0.02), MRK: 52.09 (-0.63), NVS: 96.55 (+0.28), CELGZ: 1.93 (+0.07)
Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015 - Summarizes all the dormant and discontinued pipeline projects
M2 - Mon Aug 17, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q7drg7/glioblastoma) has announced the addition of the "Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. Summary This, Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects - A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - AB Science - AbbVie Inc. - Actelion Ltd - Actinium Pharmaceuticals, Inc. - Actinogen Limited - Activartis Biotech GmbH - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advanced Cancer Therapeutics - Advenchen Laboratories, LLC - Agenus, Inc. - AGY Therapeutics, Inc. - Amal Therapeutics SA - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AngioChem Inc. - Apogenix GmbH - Argon Pharma S.L. - Ariad Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Axelar AB - Bexion Pharmaceuticals, LLC. - biOasis Technologies Inc. - BioCancell Ltd - Biomar Microbial Technologies - Bioncotech Therapeutics S.L. - Biovista Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/q7...ioblastoma
ATNM: 2.44 (+0.07), ADRO: 20.40 (+0.27), AMBX: (), AZN: 33.30 (+0.02), AMGN: 153.21 (+0.07), AMPE: 3.12 (+0.14), ABBV: 59.35 (-0.23), BMY: 59.22 (+0.47), AAAP: ()
Hypertension - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hypertension
M2 - Fri Aug 14, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gn56xn/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Hypertension - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: - Introduction - Hypertension Overview - Therapeutics Development - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - Hypertension - Therapeutics Assessment - Drug Profiles - Hypertension - Recent Pipeline Updates - Hypertension - Dormant Projects - Hypertension - Discontinued Products - Hypertension - Product Development Milestones Companies Mentioned - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Ahn-Gook Pharmaceutical Co., Ltd. - Alnylam Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Angion Biomedica Corp. - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Bio-inRen - Biocon Limited - Biolab Sanus Farmaceutica Ltda. - BioLineRx, Ltd. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Cellceutix Corporation - Celsion Corporation - Chong Kun Dang Pharmaceutical Corp. - CJ CheilJedang Corp. - Conatus Pharmaceuticals Inc. - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dong-A Socio Group - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/gn...pertension
CYTK: 7.31 (-0.08), CNAT: 4.44 (+0.10), CLDN: 1.22 (+0.02), LLY: 81.80 (+0.96), CLSN: 2.04 (-0.09), ASND: 20.60 (+0.05), ABBV: 59.35 (-0.23), ANAC: 141.14 (+1.10), ARNA: 2.86 (+0.15)
Systemic Lupus Erythematosus: Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Thu Aug 13, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2p7pm/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Systemic Lupus Erythematosus and enlists all their major and minor projects Companies Mentioned - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Kineta, Inc. - Kymab Limited - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - National Pharmaceutical Corp. - Neovacs SA - Nippon Chemiphar Co., Ltd. - Padlock Therapeutics, Inc. - Pfizer Inc. - Plexxikon Inc. - RedHill Biopharma Ltd. - Redx Pharma Ltd - Resolve Therapeutics, LLC - Sanofi - Sarepta Therapeutics, Inc. - SATT Conectus Alsace SAS - SBI Biotech Co., Ltd. - Seattle Genetics, Inc. - Takeda Pharmaceutical Company Limited - Therapix Biosciences Ltd - UCB S.A. - Xencor, Inc. - XTL Biopharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/c2...emic_lupus
RDHL: 14.47 (+0.62), JNJ: 92.93 (+0.21), ANTH: 8.03 (-0.15), SRPT: 35.94 (+1.49), ABBV: 59.35 (-0.23), XNCR: 16.39 (-0.49), CBMG: 22.85 (-0.01), MGNX: 26.64 (+0.29), IMMU: 2.22 (+0.01), PFE: 32.97 (+0.35), AMGN: 153.21 (+0.07), BMY: 59.22 (+0.47), GSK: 40.26 (+0.02), ARGS: 6.22 (-0.02), SGEN: 45.01 (+3.43), CELGZ: 1.93 (+0.07)
Mallinckrodt to Acquire Therakos, Boost Hospital Business
Zacks Equity Research - Zacks Investment Research - Tue Aug 11, 2:55PM CDT
Mallinckrodt (MNK) entered into a definitive agreement to acquire Therakos, Inc. from The Gores Group in a transaction valued at roughly $1.325 billion.
MNK: 82.08 (-0.92), VRX: 225.64 (-3.15), CORT: 5.06 (+0.01)
Catalyst Pharmaceuticals' Loss Wider Y/Y, Firdapse in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 11, 10:44AM CDT
Catalyst Pharmaceuticals (CPRX) reported second-quarter 2015 loss of 6 cents per share, wider than the Zacks Consensus Estimate of a loss of 7 cents.
VRX: 225.64 (-3.15), CPRX: 3.90 (-0.24), CORT: 5.06 (+0.01)
Merrimack Pharmaceuticals' Q2 Loss Wider, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 11, 9:50AM CDT
Merrimack Pharmaceuticals (MACK) reported second-quarter 2015 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 28 cents.
MACK: 10.48 (+0.04), BXLT: 35.81 (+0.80), CORT: 5.06 (+0.01)
Dyax (DYAX) Shows Strength: Stock Adds 6.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 7:51AM CDT
Dyax Corp. (DYAX) was a big mover last session, as its shares rose almost 7% on the day.
DYAX: 22.84 (+0.52)
Sarepta Posts Narrower-than-Expected Loss in Q2, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 4:58PM CDT
Sarepta Therapeutics (SRPT) reported a loss of $1.01 per share in the second quarter of 2015, much narrower than the Zacks Consensus Estimate of a loss of $1.21.
BMRN: 132.88 (-0.20), GILD: 109.63 (+2.38), SRPT: 35.94 (+1.49)
Emergent BioSolutions Tops on Q2 Earnings, Plans Spin-Off - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 4:55PM CDT
Emergent (EBS) reported earnings of 36 cents per share in the second quarter of 2015.
BIIB: 315.37 (+2.75), EBS: 32.58 (+0.39), AMAG: 53.00 (-4.65)
Jazz Pharmaceuticals Misses on Q2 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 2:12PM CDT
Jazz Pharmaceuticals (JAZZ) reported second-quarter 2015 earnings of $2.11 per share, substantially lower than the Zacks Consensus Estimate of $2.16.
GILD: 109.63 (+2.38), JAZZ: 160.62 (-0.21), LGND: 94.95 (+1.59)
Ironwood's Q2 Loss Wider than Expected, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 12:55PM CDT
Ironwood Pharmaceuticals (IRWD) reported a second-quarter 2015 loss of 34 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents.
AGN: 295.24 (+1.64), IRWD: 11.62 (+0.50), EXAS: 19.64 (-0.36)
Osiris Therapeutics' Q2 Earnings & Revenues Grow Y/Y - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 06, 12:50PM CDT
Osiris Therapeutics' (OSIR) revenues are growing significantly - the sales force effort, improving Medicare and private reimbursement coverage should continue driving revenues.
GILD: 109.63 (+2.38), OSIR: 19.32 (+0.52), AMAG: 53.00 (-4.65)
